Journal
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
Volume 1802, Issue 1, Pages 198-204Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.bbadis.2009.07.005
Keywords
Amyloid beta; Alzheimer's disease; Mitochondria; Mitochondrial permeability transition pore; Cyclophilin D; Cyclosporine A
Funding
- USPHS [PO1 AG17490]
- Alzheimer Association
- NATIONAL INSTITUTE ON AGING [P01AG017490] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Amyloid beta (A beta) plays a critical role in the pathophysiology of Alzheimer's disease. increasing evidence indicates mitochondria as an important target of A beta toxicity; however, the effects of A beta toxicity on mitochondria have not yet been fully elucidated. Recent biochemical studies in vivo and in vitro implicate mitochondrial permeability transition pore (mPTP) formation involvement in A beta-mediated mitochondrial dysfunction. mPTP formation results in severe mitochondrial dysfunction such as reactive oxygen species (ROS) generation, mitochondrial membrane potential dissipation, intracellular calcium perturbation, decrease in mitochondrial respiration, release of pro-apoptotic factors and eventually cell death. Cyclophilin D (CypD) is one of the more well-known mPTP components and recent findings reveal that A beta has significant impact on CypD-mediated mPTP formation. In this review, the role of A beta in the formation of mPTP and the potential of mPTP inhibition as a therapeutic strategy in AD treatment are examined. (C) 2009 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available